Annual Report FY 2025-26
For nearly three decades, we have been the strategic execution partner behind some of the most consequential operational transformations in life sciences, defining and running the next-generation operating models that power the industry’s future.
The next era of life sciences will be defined by AI at work. As the industry pivots to AI-led operating models, Indegene is already putting them to work at scale. For us, Generative AI is not a future promise; it is the natural evolution of our core discipline. We are not experimenting at the edges; we are embedding AI into the mission-critical workflows we have managed for decades.
We are actively defining the Next-Gen Operating Model through our operational north stars: from One-Click Submissions and Human-less MLR to AI-Embedded Engagement and Proactive Pharmacovigilance.
We do not merely advise and exit. We design, run, and evolve AI-embedded operations, taking enterprise accountability for outcomes that turn organizational complexity into sustained performance. Because the future of life sciences will not be shaped by AI potential alone, but by those who can operationalize it at scale.
27 Years
Years of deep healthcare expertise
5,500+
People (>27% are deep healthcare specialists)
80+ Markets
Present in
9.3%
Top client
68.6%
Top 20 clients
Who We Are
Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle.
Trusted by the world’s top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale. We combine deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations.
Commercial
Medical
R&D
Safety
AI & Platforms
What We Do
From the first molecule to the last patient interaction, Indegene supports life sciences organizations at every stage of the product lifecycle.
Discovery & Evidence
3x
Faster enrollment
Regulatory & Compliance
65%
Faster submissions
Commercial Launch
6x
Faster to market
Content & Engagement
3M+
HCP profiles
Patient & Outcomes
80%
Better adherence
~50% of code developed for internal products with AI support, improving developer productivity and accelerating time-to-delivery while maintaining quality controls.
Enterprise program that enables broad participation through Innovation Champions, a GenAI sandbox, mentorship, and recognition - turning ideas into prototypes faster. More than 15 prototypes received in two months.
Achieved the highest process maturity level, strengthening predictability, scalability, and continuous improvement through statistically managed, data-driven processes.
By automating repeatable workflows, reducing cycle time, and freeing capacity for higher-value work.
Why Indegene Wins
Indegene’s capabilities span the entire commercialization value chain – from evidence generation through lifecycle optimization – supported by a common data, analytics and technology backbone:
Research & Development
Precision at every step, from first molecule to clinical proof.
Pharmacovigilance & Regulatory Affairs
Compliant, submission-ready and defensible across every market.
Launch & Commercialization
Commercial execution that turns market entry into market leadership.
Medical & Commercial Engagement
Scientific credibility, delivered to the people who prescribe and decide.
Lifecycle Optimization
Sustained performance, long after the launch excitement fades.
Dear Stakeholders,
As FY 2025-26 draws to a close – a defining year in many ways – I find myself in a familiar and treasured place: writing to you with satisfaction for the year behind us, gratitude for the trust placed in us, and genuine excitement about what lies ahead. As FY 2025-26 draws to a close – a defining year in many ways – I find myself in a familiar and treasured place: writing to you with satisfaction for the year behind us, gratitude for the trust placed in us, and genuine excitement about what lies ahead.
Performance At A Glance
FY26 marked a milestone year for Indegene. We delivered 23.6% revenue growth to ₹35.1 billion, combining strong underlying business momentum with the successful integration of acquisitions, while generating ₹650 crores of operating cash flow.
As we enter FY27, we are focused on translating the investments made over the last year into margin expansion, while remaining disciplined in capital allocation. Our priority is to deploy capital towards high-return opportunities in AI, innovation, and strategic growth, while continuing to strengthen cash generation and long-term shareholder value.
— Suhas Prabhu, CFO
₹35,105 million
Revenue
23.6%
vs FY 2024-25
₹6,247 million
EBITDA
11.1%
vs FY 2024-25
₹4,011 million
PAT
1.4%
vs FY 2024-25
₹14,814 million
Bank balances and current investment
11.0%
vs FY 2024-25
₹31,387 million
Net worth
20%
vs FY 2024-25
Awards and Recognition
Our pursuit of innovation, people-first culture, and responsible practices has earned us recognition across multiple areas. From technology and GenAI leadership to talent practices and sustainability, these accolades reflect our commitment to excellence and the impact we continue to create.
Leader in ISG’s Provider Lens™ Evaluation for Life Sciences Digital Services in Commercial Operations – Digital Evolution (Service Providers) Quadrant
Leader in Everest Group’s Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment
Disruptor in Avasant’s Life Sciences Digital Services RadarView™
Horizon 2 – Enterprise Innovators in HFS Horizons: Life Sciences Service Providers
Innovators in Avasant’s Veeva Services RadarView™
BIG’s AI Excellence Award: NEXT Unified Data Platform
Data Breakthrough Award for Data Solution of the Year: NEXT Unified Data Platform
The Stevie Awards (Bronze): GenAI for R&D Medical Writing
GPTW Top 50 India’s Best Workplaces™ in Health & Wellness
Best Companies for Women in India – Hall of Fame (Avtar & Seramount)
People Business Consulting Top 50 Companies with Great Managers in India
AIM Top 50 Best Firms for Data Scientists to Work For
Brandon Hall Group’s HCM Excellence Award (Gold) for Learning and Development
Leader Rating (80/100) in ESG by NSE Sustainability Ratings and Analytics
Appraised at level 5 of ISACA’s Capability Maturity Model Integration
Cybervadis Platinum for Cybersecurity Maturity
Ecovadis Silver Medal for Sustainability and Responsible Business Practices
